EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access

Dual Immune Check Point Blockade in MGMT -Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial

Andrew B Lassman iD, Mei-Yin C Polley iD, Fabio M Iwamoto, Andrew E Sloan iD, Tony J C Wang iD, Kenneth D Aldape iD, Jeffrey S Wefel iD, Vinai Gondi iD, Alonso N Gutierrez, Mohammed H Manasawala, Mark R Gilbert iD, Erik P Sulman iD und 10 weitere

Journal of Clinical Oncology · 2025

DOI: 10.1200/jco-25-00618 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Andrew B Lassman und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neuro-Oncology, Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, DNA Modification Methylases, DNA Repair Enzymes. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE New therapies for glioblastoma are needed, especially MGMT -unmethylated (u MGMT ) disease. NRG Oncology BN002 (phase I) demonstrated safety and suggested efficacy of ipilimumab (ipi) with nivolumab (nivo) in newly diagnosed glioblastoma, leading to this phase II/III trial. METHODS Adults with newly diagnosed u MGMT glioblastoma and Karnofsky performance status (KPS) ≥70 were randomly assigned to radiotherapy with either immunotherapy (ipi and nivo) or temozolomide (TMZ), stratified by recursive partitioning analysis (RPA) class and intention to use tumor treating fields. With 95% power to detect a hazard ratio (HR) ≤0.58 for progression-free survival (PFS) at a one-sided significance level ( P ) of .15, superior PFS with immunotherapy in phase II would lead to phase III overall survival (OS) testing. Corticosteroids were disallowed when starting immunotherapy. Diagnosis, biomarkers, and PFS were centrally assessed. RESULTS One hundred fifty-nine participants were randomly assigned (79 immunotherapy and 80 TMZ). Arms were well balanced for age (median 60 years, range, 28-79), sex (male n = 105, 66%), KPS (90-100 n = 97, 61%), resection extent (gross total, n = 103, 65%), and RPA class (III, n = 16, 10%; IV, n = 116, 73%; V, n = 27, 17%). A preplanned analysis of phase II data conducted after 100 centrally determined PFS events showed no significant PFS improvement for ipi and nivo versus TMZ (median 7.7 months v 8.5 months, HR, 1.47 [70% CI, 1.19 to 1.83]; one-sided P = .96 [95% CI, 0.98 to 2.2]). OS is immature (>50% alive) but with no observed difference between arms (median approximately 13 months each, HR, 0.95 [95% CI, 0.61 to 1.49]; P = .36). CONCLUSION Ipi and nivo did not improve PFS among patients with newly diagnosed u MGMT glioblastoma versus TMZ. Accrual closed permanently; the trial will not proceed to phase III. No new safety signals were identified. Molecular correlative analyses and survival follow-up are ongoing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBrain NeoplasmsDNA Modification MethylasesDNA Repair EnzymesGlioblastomaImmune Checkpoint InhibitorsTumor Suppressor ProteinsAdultAgedFemaleHumansMaleMiddle AgedDNA MethylationIpilimumabNivolumabProgression-Free SurvivalTemozolomide

Substanzen

DNA Modification MethylasesDNA Repair EnzymesImmune Checkpoint InhibitorsIpilimumabMGMT protein, humanNivolumabTemozolomideTumor Suppressor Proteins

Autor:innen und Institutionen

  • Division of Neuro-Oncology, Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY.
  • Herbert Irving Comprehensive Cancer Center, New York, NY.
  • NewYork-Presbyterian, New York, NY.
  • NRG Oncology Statistics and Data Management Center, Philadelphia, PA.
  • Department of Public Health Sciences, University of Chicago, Chicago, IL.
  • Department of Neurosurgical Oncology, Piedmont Health, Atlanta, GA.

ORCID-Profile: Andrew B Lassman, Mei-Yin C Polley, Andrew E Sloan, Tony J C Wang, Kenneth D Aldape, Jeffrey S Wefel, Vinai Gondi, Mark R Gilbert, Erik P Sulman, Jedd D Wolchok, Elizabeth C Neil, Matija Snuderl, Minesh P Mehta

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Lassman, A. B., Polley, M. C., Iwamoto, F. M., Sloan, A. E., Wang, T. J. C., Aldape, K. D., Wefel, J. S., Gondi, V., Gutierrez, A. N., Manasawala, M. H., Gilbert, M. R., Sulman, E. P., Wolchok, J. D., Green, R. M., Neil, E. C., Lukas, R. V., Goldlust, S. A., Snuderl, M., Galbraith, K., …, & Mehta, M. P. (2025). Dual Immune Check Point Blockade in MGMT -Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-00618

Vancouver

Lassman AB, Polley MC, Iwamoto FM, Sloan AE, Wang TJC, Aldape KD, et al. Dual Immune Check Point Blockade in MGMT -Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial. Journal of Clinical Oncology. 2025. doi:10.1200/jco-25-00618

BibTeX
@article{Lassman2025,
  author = {Lassman, Andrew B and Polley, Mei-Yin C and Iwamoto, Fabio M and Sloan, Andrew E and Wang, Tony J C and Aldape, Kenneth D and Wefel, Jeffrey S and Gondi, Vinai and Gutierrez, Alonso N and Manasawala, Mohammed H and Gilbert, Mark R and Sulman, Erik P and Wolchok, Jedd D and Green, Richard M and Neil, Elizabeth C and Lukas, Rimas V and Goldlust, Samuel A and Snuderl, Matija and Galbraith, Kristyn and Dignam, James J and Won, Minhee and Mehta, Minesh P},
  title = {Dual Immune Check Point Blockade in MGMT -Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1200/jco-25-00618}
}
Kostenlos starten →